about
Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later.Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial.Polyphenol Levels Are Inversely Correlated with Body Weight and Obesity in an Elderly Population after 5 Years of Follow Up (The Randomised PREDIMED Study)The medical risks of obesity.Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes.Physical health monitoring of patients with schizophrenia.Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications.The Look AHEAD Trial: A Review and Discussion Of Its OutcomesEffect of weight loss with lifestyle intervention on risk of diabetes.Waist circumference correlates with metabolic syndrome indicators better than percentage fat.Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the AmeriWeight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the AmeriThe relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus.Evaluation of a new whole room indirect calorimeter specific for measurement of resting metabolic rate.Achieving weight and activity goals among diabetes prevention program lifestyle participants.Sex hormone binding globulin and sex steroids among premenopausal women in the diabetes prevention program.The metabolic syndrome: how to approach differing definitions.Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventionsThe obesity epidemic: pharmacological challenges.Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.Testosterone and depressive symptoms among men in the Diabetes Prevention Program.Metabolic flexibility in response to glucose is not impaired in people with type 2 diabetes after controlling for glucose disposal rate.Effect on Nitrogen Balance, Thermogenesis, Body Composition, Satiety, and Circulating Branched Chain Amino Acid Levels up to One Year after Surgery: Protocol of a Randomized Controlled Trial on Dietary Protein During Surgical Weight Loss.A New Whole Room Indirect Calorimeter for Measurement of the Energetics of Exercise.Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.Changes in skeletal muscle and organ size after a weight-loss intervention in overweight and obese type 2 diabetic patients.EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program.Improving health outcomes: future directions in the field.Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.A 12-week randomized clinical trial investigating the potential for sucralose to affect glucose homeostasis.Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial.Validation of whole room indirect calorimeters: refinement of current methodologies.
P50
Q27331884-D7005EA2-CE50-47DF-9019-7353831C6336Q30548796-84615062-2885-4F6A-890E-76BC80204D6EQ31144410-22EDAA29-6FF9-4A11-A92B-297DB2347078Q33646647-9982138E-2B52-4E64-843C-759529F348AEQ33749276-1927AECD-FA1B-4F46-B712-BCCF8A1BA5BAQ33888248-5114A7CF-C2CE-48AF-ADA4-EE0420BD6374Q34073450-E72ED491-E82D-4C97-BDAB-301FE0654931Q34337506-4B6624AA-22BA-4FCC-8512-2B6481ACEDEEQ34895164-49577D1A-DCD8-4439-B0B6-C0F60B50A807Q35116229-C875196F-68A7-4B7E-A08E-4C578C265113Q35568884-ECCF5C2A-7A2F-4C4D-AB00-88F9BC92CC90Q35846454-7C747C36-617E-49A0-9CEE-A3BBCB54E908Q35847314-FD08C0CF-E9DD-4AAA-B852-D26D5ACE8EBFQ35847375-A79436B5-B2CF-40DB-8821-BC6B1A61C06FQ36147100-5F18AB75-D4E7-4A5E-86F2-A11C2AC24EADQ36301927-5C57734D-BF92-40BC-8523-F7A824F4047EQ36825741-F512030F-E847-4038-BBDD-9A79F8629968Q36982031-715D3E3B-1F8A-47CB-8DED-BFAA16F9758FQ36983365-670DFBAF-9823-4233-AC64-32776740C58CQ37061253-E2BAF8F9-06F8-499C-8740-149D96DE15B0Q37135020-AFFCE794-680B-491C-ACB6-693510DCA935Q37151277-E262888C-316C-4263-8189-6C5786BC780AQ37351641-1228E7DA-F01B-44D5-80DF-371898771F61Q37374143-82DA7555-9F40-47CE-B895-03F608F76159Q37497243-3E5387B6-DBDC-45FD-B8C7-05B3E5BB7A02Q37626013-139FA2ED-5223-4DB1-8999-D0C72654EC6EQ38377477-8F41A7C0-2990-4089-9ABC-C620FAD1372FQ38385024-8CD150E9-B842-4803-A035-C9B9974DB4EFQ38390421-D79D8A38-AA7C-4549-B520-CEC1B4C1F522Q38645269-8D9BED1D-D239-4A69-A666-510ADC13D0F3Q39158039-60BDAAD1-0474-4845-91CC-E0B7BFC2492BQ39534474-2AA01390-2E67-4821-92A3-87459E52E2C9Q40145195-0117EA22-CB41-4E32-9E7A-302C94A792E1Q40425815-8A229BCB-4B6C-4914-80BE-091A20093ABCQ42732735-BE57EE70-A893-4B47-9C8F-BD7D8F3457E0Q44773204-20F34A99-3CBB-4FE5-BAB2-FE42FADCBB6DQ46183970-A8609F1D-9C19-48E3-89E0-143BA31B3996Q46809875-21600EF7-03D1-469A-A9C6-985EF55A3691Q46845313-144CBE7E-2991-48E5-AECA-F4078D93551BQ47128422-DAAB43DF-61CA-4E81-9B78-FD502DBDF5DD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xavier Pi-Sunyer
@ast
Xavier Pi-Sunyer
@en
Xavier Pi-Sunyer
@es
Xavier Pi-Sunyer
@nl
type
label
Xavier Pi-Sunyer
@ast
Xavier Pi-Sunyer
@en
Xavier Pi-Sunyer
@es
Xavier Pi-Sunyer
@nl
prefLabel
Xavier Pi-Sunyer
@ast
Xavier Pi-Sunyer
@en
Xavier Pi-Sunyer
@es
Xavier Pi-Sunyer
@nl
P106
P19
P21
P31
P496
0000-0003-2207-2008